Harmony Biosciences Holdings Management
Management criteria checks 3/4
Harmony Biosciences Holdings' CEO is Jeffrey Dayno, appointed in Jan 2023, has a tenure of 2.33 years. total yearly compensation is $7.15M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth $204.65K. The average tenure of the management team and the board of directors is 4.1 years and 4.6 years respectively.
Key information
Jeffrey Dayno
Chief executive officer
US$7.1m
Total compensation
| CEO salary percentage | 10.01% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.01% |
| Management average tenure | 4.1yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 26% Share Price Climb
May 20
Why Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Are Better Than They Seem
May 13Results: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 09Harmony Biosciences: A Compelling Risk-Reward Opportunity
Mar 24Harmony Biosciences Holdings, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 28Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Shares Not Telling The Full Story
Feb 15Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech
Jan 24Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points
Nov 11Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 31Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt?
Oct 30Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Sep 25
Pitolisant HD's Innovations And Critical Expansions Set To Surge Revenue And Solidify Market Dominance
Expanding the patient base and treatment efficacy for narcolepsy with the high-dose program of pitolisant and pursuing additional indications will significantly grow future revenues.Harmony Biosciences: Advancing An Expanded Pipeline
Aug 15Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet
Jul 15Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Jun 07Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 03These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely
Apr 04Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings
Feb 09Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Mar 21Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?
Dec 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$153m |
| Dec 31 2024 | US$7m | US$715k | US$145m |
| Sep 30 2024 | n/a | n/a | US$123m |
| Jun 30 2024 | n/a | n/a | US$115m |
| Mar 31 2024 | n/a | n/a | US$138m |
| Dec 31 2023 | US$4m | US$613k | US$129m |
| Sep 30 2023 | n/a | n/a | US$151m |
| Jun 30 2023 | n/a | n/a | US$200m |
| Mar 31 2023 | n/a | n/a | US$189m |
| Dec 31 2022 | US$762k | US$459k | US$181m |
| Sep 30 2022 | n/a | n/a | US$156m |
| Jun 30 2022 | n/a | n/a | US$58m |
| Mar 31 2022 | n/a | n/a | US$49m |
| Dec 31 2021 | US$703k | US$446k | US$35m |
| Sep 30 2021 | n/a | n/a | US$12m |
| Jun 30 2021 | n/a | n/a | US$17m |
| Mar 31 2021 | n/a | n/a | -US$7m |
| Dec 31 2020 | US$3m | US$431k | -US$64m |
| Sep 30 2020 | n/a | n/a | -US$110m |
| Jun 30 2020 | n/a | n/a | -US$146m |
| Mar 31 2020 | n/a | n/a | -US$165m |
| Dec 31 2019 | US$672k | US$414k | -US$187m |
Compensation vs Market: Jeffrey's total compensation ($USD7.15M) is about average for companies of similar size in the US market ($USD6.15M).
Compensation vs Earnings: Jeffrey's compensation has increased by more than 20% in the past year.
CEO
Jeffrey Dayno (67 yo)
Dr. Jeffrey M. Dayno, M.D. serves as President, Chief Executive Officer and Director at Harmony Biosciences, LLC since 2023 and served as its Interim President and Chief Executive Officer since January 06,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Non-Executive Chairman | 7.6yrs | US$40.00k | 0.44% $ 8.7m | |
| President | 2.3yrs | US$7.15m | 0.010% $ 204.7k | |
| Executive VP | 4.2yrs | US$3.07m | 0% $ 0 | |
| Executive VP and Chief Medical & Scientific Officer | 1yr | US$5.73m | 0.019% $ 375.6k | |
| Executive VP & Chief Strategy Officer | 6.4yrs | US$2.09m | 0.0029% $ 56.5k | |
| VP & Head of Investor Relations | no data | no data | no data | |
| General Counsel & Corporate Secretary | 4.3yrs | no data | no data | |
| Chief Compliance Officer | 4yrs | no data | no data | |
| Chief Human Resources Officer | no data | no data | no data | |
| Senior VP & Chief Corporate Affairs Officer | no data | no data | no data | |
| Executive VP & Chief Commercial Officer | less than a year | no data | no data | |
| Senior Manager of Patient Advocacy & Harmony Biosciences | no data | no data | no data |
Experienced Management: HRMY's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Non-Executive Chairman | 7.6yrs | US$40.00k | 0.44% $ 8.7m | |
| President | 2.3yrs | US$7.15m | 0.010% $ 204.7k | |
| Independent Director | 7.7yrs | no data | no data | |
| Independent Director | 4.5yrs | US$180.01k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$302.99k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$235.01k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$178.01k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$175.01k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$180.01k | 0% $ 0 | |
| Independent Director | less than a year | no data | no data |
Experienced Board: HRMY's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 19:16 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Harmony Biosciences Holdings, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Charles Duncan | Cantor Fitzgerald & Co. |
| David Hoang | Citigroup Inc |